PWA
RIGL icon

Providence Wealth Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Providence Wealth Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,000
Closed -$65.5K – 81
2024
Q1 		$65.5K Buy
5,000
+4,330
+646% +$58.4K 0.06% 78
2023
Q4 		$619K Sell
670
-2,080
-76% -$21.3K 0.56% 53
2023
Q3 		$29K Hold
2,750
– – 0.03% 69
2023
Q2 		$38K Buy
2,750
+150
+6% +$2.03K 0.04% 69
2023
Q1 		$31.2K Hold
2,600
– – 0.02% 94
2022
Q4 		$32.2K Buy
2,600
+100
+4% +$917 0.02% 94
2022
Q3 		$18K Hold
2,500
– – 0.01% 96
2022
Q2 		$32K Buy
2,500
+150
+6% +$3.01K 0.02% 97
2022
Q1 		$75K Hold
2,350
– – 0.05% 98
2021
Q4 		$57K Hold
2,350
– – 0.04% 98
2021
Q3 		$83K Hold
2,350
– – 0.06% 94
2021
Q2 		$104K Hold
2,350
– – 0.07% 95
2021
Q1 		$80K Buy
2,350
+200
+9% +$7.92K 0.06% 93
2020
Q4 		$78K Buy
2,150
+150
+8% +$4.34K 0.06% 92
2020
Q3 		$48K Buy
2,000
+450
+29% +$11K 0.05% 85
2020
Q2 		$28K Buy
1,550
+225
+17% +$4.05K 0.03% 87
2020
Q1 		$20K Buy
1,325
+100
+8% +$2.13K 0.02% 85
2019
Q4 		$26K Buy
+1,225
New +$25.2K 0.02% 85

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Providence Wealth Advisors's RIGL Position: Q2 2024 in Review

Providence Wealth Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q2 2024, closing a stake of 5,000 shares — an estimated $65.5K sold.

Providence Wealth Advisors first reported a position in RIGL in Q4 2019 and held it in 18 quarters. The position peaked at $619K in Q4 2023. 91 funds tracked by Wall St. Rank hold RIGL as of Q2 2024.

  • Providence Wealth Advisors reported no remaining Rigel Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Providence Wealth Advisors sold 5,000 Rigel Pharmaceuticals shares in Q2 2024, an estimated $65.5K.
  • Providence Wealth Advisors first reported a position in Rigel Pharmaceuticals in Q4 2019 and held it in 18 quarters.
  • Providence Wealth Advisors's Rigel Pharmaceuticals position peaked at $619K in Q4 2023.
  • 91 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2024.

Based on Providence Wealth Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.